Clinical trial
Remission in Subjects With Crohn's Disease, 1 Year Phase
NCT00055497 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00055497 |
|---|---|
| Title | Remission in Subjects With Crohn's Disease, 1 Year Phase |
| Official title | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of Clinical Remission in Subjects With Crohn's Disease |
| Acronym | CLASSICII |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Biological |
| Interventions | Double-blind (DB) adalimumab placebo, DB adalimumab 40 mg eow, DB adalimumab 40 mg ew, OL adalimumab 40 mg |
| Enrollment | 276 |
| Start date | Aug 1, 2002 |
| Primary completion | Jan 1, 2005 |
| Completion | Dec 1, 2008 |
| First posted | Mar 5, 2003 |
| Last update posted | Apr 11, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: